Drug intelligence / Profile preview

Novicrit

Development stage: Unknown
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intravenous

Overview

Novicrit is a recombinant human erythropoietin biologic containing epoetin lambda produced in Chinese hamster ovary cells engineered to express the human erythropoietin gene. It acts as an erythropoiesis-stimulating agent by binding to and activating the erythropoietin receptor, thereby promoting red blood cell production in a manner comparable to endogenous human erythropoietin. The product was registered in Australia in January 2010 and has been used for anemia associated with chronic kidney disease including dialysis, chemotherapy-induced anemia in patients with non-myeloid malignancies, anemia in patients undergoing elective surgery with expected moderate blood loss, and myelodysplastic syndromes.

Brand names: Novicrit
Other names: epoetin lambdaepoetin lambda rch

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on Novicrit.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novicrit.

Explore the full profile